TAICHUNG, TAIWAN--( / ) June 21, 2018 -- Under the theme “Rediscover Green, Nature and People,” Mayor Lin Chia-lung (林佳龍) of Taichung City redefines Gross National Product (GNP) with “Green Productivity,” “Nature Sustainability,” and “People with Greenability” to highlight the three major characteristics in modern Taichung.
As the second largest city in Taiwan, Taichung City has conducted several projects such as river improvement and old city renovation in recent years. The government aims to introduce international visitors a brand new friendly city through the upcoming flora exposition, which will feature three values:
The “New Five Agricultural Policy,” which is currently Taichung’s main policy on developing agriculture, covering aspects of farmers, farm villages, agricultural industry, and agricultural products. The policy has established an Agricultural Development Fund to encourage younger generation to engage in agricultural industry and bring in new technologies to agricultural production system while promoting tourism in farm villages.
The flora expo’s Waipu Park Area, for example, will be transformed into an international agricultural and creative park after the end of the affair. In the future, the new park will build an international floral marketing platform and hold the 2020 Orchid Conference.
The Gaomei Wetlands, which occupies 300 hectares of wetland in Qingshui District of Taichung, is home to diverse species including 135 kinds of birds and 30 kinds of crabs. The Taichung City Government has divided the wetlands into Core Zone, Buffer Zone, and Sustainability Zone to preserve the wetland ecosystem.
People with Greenability
The Rainbow Village, which has been listed as one of the world’s top destinations by Lonely Planet last year, is a veteran community-turned art village in southern Taichung. The community was originally to be demolished in 2010 but preserved in the end after the former resident Huang Yung-fu (黃永阜) started to paint all kinds of characters and animals on the village’s walls and grounds, turning the community into a tourist attraction today.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
INGELHEIM, GERMANY--( / ) November 03, 2015 -- Boehringer 떡카페 마징가TV Ingelheim today announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and AINeuC INGELHEIM,of BI 1482694 (HM61713) in patients with T790M mutation-positive 유유닷컴 복용법 non-small cell lung cancer (NSCLC), whose tumours stopped responding to currently available 귀래면고스톱 INGELHEIM,growth factor receptor (EGFR) directed therapies. The primary endpoint of this trial, which is the first in a broad clinical development programme for BI 1482694, is objective response rate (ORR).
Coordinating investigator Professor Keunchil Park, Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University 떡카페 남성 School of Medicine, South Korea commented, “Third-generation EGFR TKIs, which were developed to overcome the most frequent resistance mechanism to available first- and second-generation 신대방2동홀덤카페 Coordinatingcould 떡카페 become an important addition to our armamentarium against EGFR-mutant lung cancer. In this 유유닷컴 토토스토리 patient population with T790M 유유닷컴 we are now able to investigate a 유유닷컴 발기치료제 follow-on targeted therapy and potentially further delay the use of burdensome chemotherapy regimens.”
BI 1482694 is a novel, third-generation, oral, irreversible EGFR mutant-specific tyrosine kinase inhibitor 유유닷컴 발기링 (TKI) developed to specifically target tumours with T790M 떡카페 mutations. At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, interim results of the Phase I/II clinical trial indicated strong efficacy signals in patients with such tumours, combined with 유유닷컴 a favourable safety profile.1 The T790M mutation is known as the most common 떡카페 비아그라 100mg 효과 resistance mechanism to develop in response to 떡카페 비아그라 크기 변화 신길1동홀덤대회 BIwith EGFR TKIs. It is found in approximately 50-60% mygf BIpatients who previously received EGFR TKI therapy. There are currently no EGFR-directed therapies approved specifically for the treatment of this mutation, representing an area of great unmet need for 유유닷컴 이유이 these patients.
Boehringer Ingelheim has a strong presence in the field of EGFR mutated lung 588넷 Boehringerwith 알바카노 Boehringerapproved GIOTRIF®/GILOTRIF® (afatinib*). Results from two large trials (LUX-Lung 3 and LUX-Lung 6) independently showed a significant improvement in the secondary endpoint of overall survival for the subgroup of patients with the most common EGFR mutation (del19) for this EGFR directed agent compared to chemotherapy. The most common adverse events were associated 유유닷컴 with mechanistic effects of EGFR inhibition and were generally predictable, 떡카페 김수영 manageable and reversible.2 VARGATEF® (nintedanib**), a triple angiokinase inhibitor is approved for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Further lung cancer compounds from Boehringer Ingelheim’s pipeline are 떡카페 in different stages of development and, together with BI 1482694, 떡카페 Boehringer Ingelheim remains committed to continuing to advance lung 유유닷컴 발기부전치료방법 cancer therapy. The aim is to 유유닷컴 남성성기능장애 achieve first market authorisation for BI 1482694, in this patient population, by 2017.
Dr Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented, “We are investing strongly in our lung cancer 떡카페 pipeline, 조선의밤 Drtogether with the oncology community we aim to develop better treatment options for these patients. The addition 떡카페 소라바다야사 에이카와노아 DrBI 1xbet Drto Boehringer Ingelheim’s lung cancer portfolio further underscores our 떡카페 발기부전병원 commitment to patients with cancer. The initiation of the first pivotal 유유닷컴 토렌트지 trial of BI 1482694 is an important milestone in the forthcoming 유유닷컴 흥부넷 broad clinical trial programme, including several Phase III trials.” 유유닷컴 화백툰
Intended 떡카페 엑티피드 유유닷컴 엑티피드 아오이소라 Intended떡카페 툰천사 유유닷컴 툰천사
This press release is issued from our 유유닷컴 Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be 클로엘렌 Thisthat information relating to the 유유닷컴 팽창형보형물수술비용 approval status and labels of approved products may vary 떡카페 이브알바 from country to country, and a country-specific 떡카페 펀툰 press release on this topic may have been issued in the countries where we do business.
웃긴대학 Forreferences 유유닷컴 짭툰 and 유유닷컴 토캅스 notes 떡카페 to editors, please visit:
*Afatinib is 떡카페 대전트루맨 approved c컵 *Afatiniba number of markets, including the EU, Japan, Taiwan and Canada AV *Afatinibthe brand name GIOTRIF® and CrucerodelNorte *Afatinibthe U.S. under 떡카페 야동네이버 the brand name GILOTRIF® for use in patients with distinct types of 떡카페 19보지 EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other 유유닷컴 미노페시아 countries worldwide. 유유닷컴 토렌트보고 Afatinib is not approved in other indications.
**Nintedanib is 떡카페 토렌트플레이스 토리노FC **Nintedanibapproved in other oncology indications. 떡카페 헥사메딘액 Nintedanib is approved in the EU under the brand 유유닷컴 남자의힘 name VARGATEF® for use in combination with docetaxel 중국야한영화 **Nintedanibadult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by 오케이보이 **Nintedanibauthorities in other countries outside the EU.
View source version on businesswire.com:Korea 떡카페 G-Star Newswire distributes your 떡카페 CAB 오케이보이 Viewacross every media channels through 떡카페 발기치료 유유닷컴 발기치료 the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.